The STING pathway and the T cell-inflamed tumor microenvironment
- 7 March 2015
- journal article
- review article
- Published by Elsevier BV in Trends in Immunology
- Vol. 36 (4), 250-256
- https://doi.org/10.1016/j.it.2015.02.003
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- STING manifests self DNA-dependent inflammatory diseaseProceedings of the National Academy of Sciences, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cellsThe Journal of Experimental Medicine, 2011
- Type I interferon is selectively required by dendritic cells for immune rejection of tumorsThe Journal of Experimental Medicine, 2011
- A signature of immune function genes associated with recurrence-free survival in breast cancer patientsBreast Cancer Research and Treatment, 2011
- Type I interferon: friend or foe?The Journal of Experimental Medicine, 2010
- Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell ImmunityScience, 2008
- STING is an endoplasmic reticulum adaptor that facilitates innate immune signallingNature, 2008
- Toll-like receptor control of the adaptive immune responsesNature Immunology, 2004